Trial Profile

A phase I study of RVX sCPD9 vaccine

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RVX sCPD9 vaccine (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

Most Recent Events

25 Jul 2024 New trial record
13 Jun 2024 According to a Rocketvax media release, RVX-sCPD9 candidate for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen. The National Institute of Allergy and Infectious Diseases (NIAID), which is a part of the National Institutes of Health, will support this phase I trial. NIAID will sponsor the study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com